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Authors’ reply
We thank Boris Cvet for his comments 
on our Article1 and agree with him 
that discovering new uses for old 
drugs oﬀ ers great promise with regard 
to making treatments for neglected 
tropical diseases in low-income and 
middle-income countries more cost-
effective and accessible. This is an 
important and neglected area.2 While 
we agree with Cvek that an imbalance 
exists in the role of governments and 
markets in investing in drug discovery 
and development, we propose that this 
is only one dimension of the problem. 
Broadly speaking, and with the large 
investments involved, we believe that 
most governments will neither have 
the resources, nor the political will, to 
invest in the clinical development of 
such drugs, and are therefore unlikely 
to make the necessary commitments. 
Instead, we suggest that governments 
can help facilitate the achievement 
of the desired right balance between 
the roles of government and markets 
through alternative but complementary 
and synergistic strategies. We propose 
four such strategies. 
First, governments can support the 
development of publicly accessible 
collections of existing drugs.3 Despite 
the promise that ﬁ nding new uses for 
existing drugs is a proven shortcut 
to improve access, comprehensive 
c o l l e c t i o n s  o f  t h e  n e a r l y 
10 000 drugs known to medicine does 
not exist.3 Government support for 
development of collections such as 
the Johns Hopkins Clinical Compound 
Library3 would go a long way to 
facilitating the rediscovery process. 
As suggested by Cvek, such a strategy 
will facilitate government-backed 
eﬀ orts to, as he put it, “systematically 
monitor positive side-effects of 
existing drugs”.
Second, governments can play an 
important part in providing incentives 
for industry to invest in discovering 
new uses for old drugs. For example, 
it could consider the extension of 
patent protection for old drugs that 
have found new uses, for example, as 
embodied in the Hatch-Waxman Act 
in the USA.4
Third, it can provide more funding 
to support research aimed at better 
understanding of the modes of action 
of drugs, a fundamental requisite in 
discovering new uses for old drugs.5 
Such support should emphasise 
the application of newer in silico 
approaches and the harnessing 
of computer power in the fields 
of computational drug discovery, 
biomedical informatics, and so-called 
big data analytics.5
In a related vein, governments 
can also facilitate and support the 
development of interdisciplinary 
collaboration networks of key stake-
holders in academia and industry. 
Taken together, these strategies will 
go a long way in repurposing and 
repositioning older drugs to help in 
health improvement globally. 
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